Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P000025/S134

MED-EL CI System

Med-El Corp. · Decision date Nov 26, 2025

FDA DECISIONP000025/S134

What did the FDA approve?

FDA records P000025/S134 as a supplement to PMA P000025, with the supplement type “Panel Track”. The recorded decision is approval, dated Nov 26, 2025.

FDA approval order statement

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) supplement for the MED-EL CI System for expanding the indication for use. The expanded device indications include children with bilateral hearing loss who meet the following criteria:The MED-EL Cochlear Implant System is intended to evoke auditory sensations via electrical stimulation of the auditory pathways for individuals with debilitating sensorineural hearing loss (SNHL) who obtain limited benefit from acoustic amplification in the ear(s) to be implanted and is indicated for the following pediatric populations: Children aged 7 months to 17 years, 11 months must demonstrate a bilateral SNHL as follows. Children implanted at 7-11 months of age should demonstrate a profound SNHL, defined by a 3-frequency pure-tone average (PTA3) of ?90 dB HL at 500, 1000, and 2000 Hz. Children implanted at 12-71 months of age should demonstrate a moderately-severe to profound SNHL in the low frequencies, defined by a PTA3 ? 55dB HL at 500, 1000, and 2000 Hz and a severe to profound SNHL in the high frequencies with thresholds not better than 70 dB HL at 2000-8000 Hz. Children implanted at 6 years to 17 years, 11 months of age should demonstrate a moderate to profound SNHL in the low frequencies, defined by a low-frequency PTA (LFPTA) >40 dB HL at 250, 500, and 1000 Hz with thresholds not better than 65 dB HL at 3000-8000 Hz. Children implanted at 7 months to 5 years, 11 months of age must also demonstrate insufficient functional access to sound with appropriately fitted amplification and aural habilitation. Children who lack the requisite language to complete word recognition testing should demonstrate either a lack of progress or plateau on an accepted scale of auditory skill development (e.g., LittlEARS Auditory Questionnaire (LEAQ), Infant-Toddler Meaningful Auditory Integration Scale (IT-MAIS)). Children with the requisite language to complete word recognition testing should demonstrate a percent correct score ? 40% on a developmentally appropriate test of word recognition (e.g., based on age, cognitive ability, language skills, and clinical judgement). Children implanted at 6 years to 17 years, 11 months of age should demonstrate limited benefit from hearing aids, defined by test scores of 50% correct or less in the ear to be implanted and 60% or less in the non-implant ear on recorded tests of monosyllabic word recognition (e.g., Consonant-Nucleus- Consonant [CNC] Words). Children implanted under 12 months of age should show repeatable behavioral test results that are consistent with objective/electrophysiological test results.¿ MED-EL strongly recommends a hearing aid trial of at least 1-3 months for children without previous hearing aid experience. Risk of ossification or lack of aidable hearing may preclude a hearing aid trial.
Regulatory pathway
PMA supplement
Supplement type
Panel Track
Clinical specialty
Ear, Nose, Throat
Decision date
Nov 26, 2025
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P000025/S134
Regulatory pathway
PMA supplement
Applicant
Med-El Corp.
Product code
MCM
Decision code
APPR
Decision date
Nov 26, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, cochlear.

Applicant
Med-El Corp.
Product code
MCM
FDA device class
3

For the original device and its historical approval scope, see PMA P000025. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P000025 · Original PMA

    COMBI 40+ COCHLEAR IMPLANT SYSTEM

  2. P000025/S134 received

    Application receipt date recorded by FDA.

  3. P000025/S134 · FDA decision

    Panel Track

  4. P000025/S137 · Related supplement

    MED-EL Cochlear Implant

  5. P000025/S136 · Related supplement

    MED-EL Cochlear Implant System

Timeline entries are records held by MedtechLedger for P000025. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P000025

Product / regulatory recordCompanyPathwayDecision dateSource
Med-El Corp.PMA approvalAug 20, 2001FDA
Med-El Corp.PMA supplementJan 23, 2026FDA
Med-El Corp.PMA supplementOct 9, 2026FDA

Explore the linked device profile

Other records with product code MCM

Product / regulatory recordCompanyPathwayDecision dateSource
Cochlear AmericasPMA supplementSep 28, 2026FDA
Cochlear AmericasPMA supplementSep 28, 2026FDA
Cochlear AmericasPMA supplementSep 28, 2026FDA
Advanced BionicsPMA supplementSep 18, 2026FDA
Advanced BionicsPMA supplementSep 4, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Med-El Corp.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Furstenweg 77a, Innsbruck, 6020

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records